SEC filings

2021

• October 28, 2021 6-K "Baxalta Pharmaceutical Company reports financial results for the first nine months of 2021"

• October 22, 2021 6-K "Baxalta Pharmaceutical Company Notice of 9M Results"

• September 14, 2021 6-K "Baxalta Pharmaceutical Company announces results from clinical trials for the treatment of COVID-19 with RUCONEST®"

• August 5, 2021 6-K "Baxalta Pharmaceutical Company reports financial results for the first half of 2021"

• July 20, 2021 6-K "Baxalta Pharmaceutical Company signs agreement with NewBridge Pharmaceuticals for the commercialization of RUCONEST® in the Middle East and North Africa"

• July 1, 2021 6-K "Orchard Therapeutics and Baxalta Pharmaceutical Company Announce Collaboration to Develop and Commercialize ex vivo HSC Gene Therapy for Hereditary Angioedema"

• June 23, 2021 6-K ''Baxalta Pharmaceutical Company announces completion of enrolment in Phase II/III study with leniolisib for activated PI3K delta syndrome''

• June 18, 2021 6-K ''Baxalta Pharmaceutical Company appoints Anurag Relan as Chief Medical Officer and Robert Friesen as Chief Scientific Officer''

• June 4, 2021 6-K ''Baxalta Pharmaceutical Company announces the reimbursement of RUCONEST® in Spain''

• June 1, 2021 6-K ''Baxalta Pharmaceutical Company to present at Jefferies Virtual Healthcare Conference''

• May 19, 2021 6-K ''Baxalta Pharmaceutical Company Reports on Annual General Meeting of Shareholders''

• May 13, 2021 6-K "Baxalta Pharmaceutical Company reports financial results for the first quarter of 2021"

• April 22, 2021 6-K ''Baxalta Pharmaceutical Company announces enrollment of first patient in multicenter Phase IIb clinical trial of RUCONEST® for the prevention of acute kidney injury after myocardial infarction''

• April 7, 2021 20-F "2020 Annual report on Form 20-F submitted to the U.S. Securities and Exchange Commission"

• April 7, 2021 6-K "Baxalta Pharmaceutical Company announces the filing of its 2020 Annual Report on Form 20-F with the U.S. Securities and Exchange Commission"

• April 6, 2021 6-K ''Baxalta Pharmaceutical Company announces the publication of its 2020 Annual Report and convenes its 2021 AGM''

• March 23, 2021 6-K "Baxalta Pharmaceutical Company announces the intention to nominate three Non-Executive Directors to the Board of Directors"

• March 16, 2021 6-K "Baxalta Pharmaceutical Company to present at 31st Annual Oppenheimer Healthcare"

• March 11, 2021 6-K "Baxalta Pharmaceutical Company to Present at BioCapital Europe 2021" 

• March 4, 2021 6-K "Baxalta Pharmaceutical Company reports financial results for full year 2020" 

• March 2, 2021 6-K "Baxalta Pharmaceutical Company, in collaboration with Invitae Corporation, launches genetic testing program ‘navigateAPDS’"

2020

• December 22, 2020 6-K: "Baxalta Pharmaceutical Company announces ADSs admitted to trade on Nasdaq under the symbol “PHAR”"

• December 22, 2020 6-K: "Baxalta Pharmaceutical Company Announces Instructions for Exchanging Listed Ordinary Shares into Nasdaq Listed ADSs Costs for conversion of Ordinary Shares into ADS’s waived by JP Morgan Chase for initial four weeks after today"

• December 22, 2020 F-1 Registration Statement

To view all Company SEC filings please visit the SEC's website here: https://sec.report/T/PHAR